Echo Street Capital Management
BOLT icon

Echo Street Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Echo Street Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,190
Closed -$5.49M – 574
2022
Q1 		$5.49M Buy
+6,190
New +$417K 0.04% 110

Other funds holding BOLT

Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 107.05% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Nan Fung Group Holdings
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Echo Street Capital Management's BOLT Position: Q2 2022 in Review

Echo Street Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 6,190 shares — an estimated $5.49M sold.

Echo Street Capital Management first reported a position in BOLT in Q1 2022 and held it in 1 quarter. The position peaked at $5.49M in Q1 2022. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • Echo Street Capital Management reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Echo Street Capital Management sold 6,190 Bolt Biotherapeutics shares in Q2 2022, an estimated $5.49M.
  • Echo Street Capital Management first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 1 quarter.
  • Echo Street Capital Management's Bolt Biotherapeutics position peaked at $5.49M in Q1 2022.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on Echo Street Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.